Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.
Advertisement
You can also search for this author in PubMed Google Scholar
MDMA has been tested as a treatment for post-traumatic stress disorder but has now garnered a vote of no confidence from FDA advisors. Credit: DEA/Science Source/Science Photo Library
In a decision that shocked some observers, key advisers to the US Food and Drug Administration (FDA) voted that the effectiveness of the party drug MDMA for treating post-traumatic stress disorder is unproven.
Members of an independent scientific advisory committee voted 9 to 2 that human trials of MDMA did not prove its efficacy. They also voted 10 to 1 that the risks of MDMA, also known as ecstasy, outweigh its benefits. The FDA does not have to follow its advisory committee’s recommendations when deciding whether to approve a drug, but often does.
The vote highlighted the difficulty of assessing psychedelic drugs and the FDA’s limited ability to evaluate psychiatric treatments. “It felt strange to vote no,” says committee member Satish Iyengar, a statistician at the University of Pittsburgh in Pennsylvania, given that the drug’s effects seemed so strong. “There were just too many problems with it.”
The vote took place at a meeting on 4 June in Silver Spring, Maryland.
MDMA is a synthetic compound that can evoke euphoria and raise energy levels. It has already been approved for limited use in Australia to treat post-traumatic stress disorder (PTSD) and depression.
For decades, the non-profit Multidisciplinary Association for Psychedelic Studies (MAPS) in San Jose, California, has been running MDMA clinical trials and campaigning for legalization of psychedelic drugs worldwide. The association’s commercial arm, Lykos Therapeutics in San Jose, has developed an MDMA treatment protocol involving a series of psychotherapy sessions, along with three sessions in which a team of two therapists administers the drug. According to the company, the idea is that MDMA is not a treatment in itself, but rather helps people to open up to their therapists about traumatic events that might otherwise be difficult to confront.
In its application to the FDA, Lykos cited two clinical trials1,2 in which a total of around 200 people with PTSD received either MDMA or a placebo. More than 80% of those who received MDMA saw significant improvements in their symptoms. And the effect seemed to persist when investigators followed up with a subset of these participants between 6 and 24 months later.
But scientists on the FDA committee had a number of concerns about Lykos’s studies, which they felt were lacking crucial psychological and physiological safety data. A major concern was the fact that participants — and their therapists — could almost always tell whether they had received MDMA or a placebo. An FDA report released ahead of the meeting called the data “challenging to interpret”.
How ecstasy and psilocybin are shaking up psychiatry
How ecstasy and psilocybin are shaking up psychiatry
“The fact is you just can’t blind these studies,” FDA psychiatry division director Tiffany Farchione said at the meeting. In 2016, MAPS and the FDA agreed on a protocol in which independent assessors who had not taken part in the trial would evaluate each person’s psychiatric progress. But both FDA staff and the advisory committee remained worried that people’s expectations of receiving a drug would affect their response to it.
Other concerns included the fact that around 40% of the participants had taken illicit MDMA before the trial, potentially biasing the sample. And many had sought other treatments — including psychedelic drugs — between the trial and the follow-up, suggesting that their symptoms might have persisted and that their improvement might not have been due entirely to MDMA.
Many of the advisory committee members’ questions centred on the role of psychotherapy. Lykos has developed a therapy protocol that would be administered along with the drug. But the FDA does not regulate psychotherapy. The most it can do is ensure that medical practitioners overseeing the drug’s administration provide some therapy.
Lykos’s protocol gives therapists substantial discretion in how they treat clients, which left some committee members concerned that the psychotherapy that trial participants received might have varied depending on whether they had taken MDMA or a placebo. Committee members pointed out that a good therapist could make a useless drug seem effective, and that there is no way to disentangle the two effects. Panel members also worried about how therapists would be trained, and called for strong regulations to protect people from abuse by clinicians when under the influence of the drug.
Potent psychedelic drug banishes PTSD, small study finds
Potent psychedelic drug banishes PTSD, small study finds
Farchione says she hoped the advisory committee would help the agency to address these issues, particularly given that many other companies are studying psychedelic therapies that the FDA will eventually need to evaluate. “I think we are charting new territory, and we want to set it up right,” she says.
Further raising concerns, a report from the Institute for Clinical and Economic Review, a non-profit group in Boston, Massachusetts, that analyses medical procedures, includes allegations that people who’d had bad experiences in the initial trials had been discouraged from participating in the follow-up study. Lykos denied this at the committee meeting, and the FDA will complete an investigation before it makes a decision on the drug.
“I was absolutely shocked” by the vote, says psychiatrist Rachel Yehuda at the Icahn School of Medicine at Mount Sinai in New York City, who was not on the committee. “It was very disappointing.” She says the experts brought up good points during the 8-hour hearing, particularly about the safety of people receiving treatment. She hopes that the FDA will look for ways to address these concerns instead of simply not approving the drug. “I want us to have learned from the committee’s wisdom.” The FDA is expected to issue a decision in August.
In a statement Lykos said: “While we are disappointed in the vote, we are committed to continuing to collaborate with the FDA with their ongoing review” of the drug-approval application over the coming weeks.
doi: https://doi.org/10.1038/d41586-024-01622-3
Mitchell, J. M. et al. Nature Med. 27, 1025–1033 (2021).
Article PubMed Google Scholar
Mitchell, J. M. et al. Nature Med. 29, 2473–2480 (2023).
Article PubMed Google Scholar
Download references
Reprints and permissions
Psychedelic drug MDMA moves closer to US approval following success in PTSD trial
Australia to prescribe MDMA and psilocybin for PTSD and depression in world first
US could soon approve MDMA therapy — opening an era of psychedelic medicine
Psychedelic treatments are speeding towards approval — but no one knows how they work
Sleep deprivation disrupts memory: here’s why
News
Alzheimer’s drug with modest benefits wins backing of FDA advisers
News
This injectable gel can help to diagnose brain injury — then it disappears
News
Hope, despair and CRISPR — the race to save one woman’s life
News Feature
Embryo models need consistent ethical oversight
Correspondence
A Second Space Age Spanning Omics, Platforms, and Medicine Across Orbits
Perspective
Autistic people three times more likely to develop Parkinson’s-like symptoms
News
Neural pathways for reward and relief promote fentanyl addiction
News & Views
Internet use and teen mental health: it’s about more than just screen time
Correspondence
Investigations on Alzheimer's disease pathology and the search for novel therapeutic strategies.
Montréal, Quebec (CA)
Prof. A. Claudio Cuello
Postdoctoral positions funded by NIH are for study of meiosis and spermatogonial stem cells using mouse models. Generous stipend and benefits.
Philadelphia, Pennsylvania (US)
University of Pennsylvania – Department of Biomedical Sciences
Associate or Senior Editor (Materials Science) Organization: Nature Communications Location(s): New York, Jersey City, Philadelphia, Beijing, Hong …
New York (US)
Springer Nature Ltd
Associate or Senior, Nature Medicine: Infectious Diseases New York, Shanghai or Beijing – Hybrid Working Application Deadline: August 1, 2024 Nat…
New York City, New York (US)
Springer Nature Ltd
Funded investigator has an immediate opening for a post-doctoral fellow to develop therapies for genetic diseases.
Johns Hopkins School of Medicine, East Baltimore Campus
Johns Hopkins University Department of Medicine
You have full access to this article via your institution.
Psychedelic drug MDMA moves closer to US approval following success in PTSD trial
Australia to prescribe MDMA and psilocybin for PTSD and depression in world first
US could soon approve MDMA therapy — opening an era of psychedelic medicine
Psychedelic treatments are speeding towards approval — but no one knows how they work
An essential round-up of science news, opinion and analysis, delivered to your inbox every weekday.
Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.
© 2024 Springer Nature Limited